Why are compounding pharmacies being shut down - and what insurance covers it?

FDA enforcement targeting 503A pharmacies that compound for office use without patient-specific prescriptions or that compound from bulk substances not on the 503A approved list. This has intensified in the GLP-1 compounding category as FDA reasserts position post-shortage. Closures often follow Warning Letters with months of remediation pressure rather than instant shutdowns.

State pharmacy board action for USP 797 / 800 environmental monitoring, beyond-use dating, and competency training failures. State boards have increased inspection frequency for sterile-compounding pharmacies and use license suspension as an escalation tool.

Carrier withdrawal from the GLP-1 compounding subcategory. Several specialty pharmacy carriers added non-FDA-approved drug exclusions to renewal endorsement schedules in 2025-2026, sometimes mid-policy, leaving operators with unmarketable risks.

Regulatory defense coverage (often endorsed onto druggist professional liability or D&O) pays defense costs for state board and FDA enforcement actions. Limits typically run $250K-$1M and do not cover fines or remediation costs.

Products liability tail coverage protects against patient injury claims arising from preparations dispensed before closure. Operators who close should buy extended reporting period (tail) coverage on any claims-made policies to address the legacy exposure.

Business interruption coverage (when on a manuscript form) may respond to forced operational suspension, but standard property forms typically do not cover regulatory shutdowns as a covered cause of loss.